Biomarkers for Proof-of-Mechanism & Proof-of-Concept Trials in IgA Nephropathy
Time: 12:00 pm
day: Conference Day One
Details:
- Pinpointing the criticality of treatment response biomarkers in the development of promising investigational therapeutics for IgA nephropathy
- Using biomarkers to support drug development decisions, demonstrate mechanisms of drug action and predict kidney function & kidney tissue damage
- Discover how integrating biomarker insights from clinical trials and real-world studies will accelerate the development of therapeutics and biomarkers with the potential to improve the lives of patients living with kidney diseases
